Forward to a friend |
Subscribe | The Record Archive | Contacts | bcbsm.com | Print this article
|
November 2024
HCPCS replacement codes established, effective Oct. 1, 2024J1749 replaces C9399, J3490, J3590, J9999 when billing for Aurlumyn (iloprost) The Centers for Medicare & Medicaid Services has established a permanent procedure code for specialty medical drug Aurlumyn™ (iloprost). All services through Sept. 30, 2024, will continue to be reported with codes C9399, J3490, J3590 and J9999. All services performed on and after Oct. 1, 2024, must be reported with J1749. J9329 replaces C9399, J3490, J3590, J9999 when billing for Tevimbra (tislelizumab-jsgr) CMS has established a permanent procedure code for specialty medical drug Tevimbra® (tislelizumab-jsgr). All services through Sept. 30, 2024, will continue to be reported with codes C9399, J3490, J3590 and J9999. All services performed on and after Oct. 1, 2024, must be reported with J9329. Q5135 replaces C9399, J3490, J3590, J9999 when billing for Tyenne (tocilizumab-aazg) CMS has established a permanent procedure code for specialty medical drug Tyenne® (tocilizumab-aazg). All services through Sept. 30, 2024, will continue to be reported with codes C9399, J3490, J3590 and J9999. All services performed on and after Oct. 1, 2024, must be reported with Q5135. Prior authorization is required through the Medical Benefit Drug Program for Q5135 for all groups unless they are opted out of the program. For groups that have opted out of the prior authorization program, this code is covered for its U.S. Food and Drug Administration-approved indications. |
|
No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.
|